LIS + IMS + AI SOLUTIONS
UNDERGOING FDA CERTIFICATION00:00:00 EDT
WHO IT'S FOR  /  TWO DOORS

▸ PATHOLOGY, REBUILT AROUND DIGITAL

Two doors,
one platform.

NovinoAI is a digital pathology software company. Labs and hospital networks license our technology. Pharma partners with us on research. Whichever door you come through, you land on the same platform — and the same team.

01  /  for diagnostic labs  /  path.for(audience)
[ 01 ]

▸ FOR DIAGNOSTIC LABS

License the platform.
Keep your scanners.

Plug FlexLIS into the scanners you already own, connect the EMRs your clinicians already use, and turn on AI modules when you're ready. No six-figure capex, no rip-and-replace.

  • ▸  FlexLIS LIS + IMS — cloud-hosted, HIPAA-eligible
  • ▸  Compatible with most major whole-slide scanners
  • ▸  AI modules for GI, GU, lung, cytology, QC
  • ▸  4-week typical deployment, 24/7 support
PRICING & PLANS →
FlexLIS LIS — case worklist
// FlexLIS LIS · case worklist
02  /  for pharma + research  /  path.for(audience)
[ 02 ]

▸ FOR PHARMA + RESEARCH

Your question.
Our research pipeline.

Tell us the biomarker, the trial, or the molecule. We digitize slides, annotate, train AI, validate at clinical scale — and deliver the data and the model.

  • ▸  Whole-slide digitization for tissue banks and sponsor studies
  • ▸  Custom AI model development on your cohorts
  • ▸  Clinical-trial pathology with standardized central review
  • ▸  Published collaborations with major academic medical centers
SEE PUBLICATIONS →
▸ COHORT ANALYSIS · PD-L1 BIOMARKER STUDY
n = 1,247 lung biopsies · 12 sites · run 2026-Q1
AUC 0.913 · PD-L1 TPS correlation 0.87
“

Three different departments. Three different tools.
We replaced all of them with FlexLIS and stopped arguing about pathology infrastructure.

E
Elena Vasquez
COO · Genesis Health Sciences

▸ Ready to modernize your lab?

Let's Bring AI
to Your Pathology.

Email Info@NovinoAI.com →